Dong-A ST Confirms Non-Inferiority of SGLT2 Inhibitor Compared to Original Forxiga

"Similar Clinical Results Across All Related Indicators"

Dong-A ST announced on June 8 that it presented the results of a clinical trial comparing the SGLT-2 inhibitor diabetes treatment DA-2811 (brand name Dafapro) and Forxiga at the American Diabetes Association (ADA) conference.

During the poster presentation, Professor Junhwa Hong of the Department of Endocrinology at Daejeon Eulji University Hospital introduced the clinical results under the theme "Comparison of Metabolic, Hepatic, Renal, and Hemodynamic Effects of DA-2811 and Forxiga in Patients with Type 2 Diabetes Mellitus." This clinical trial was a multicenter, randomized, double-blind, active-controlled, parallel-group study conducted to evaluate the efficacy and safety of DA-2811 or Forxiga administered for 24 weeks to 225 patients with type 2 diabetes.

At ADA 2026, Professor Junhwa Hong from Daejeon Eulji University Hospital (left) and Professor Sungrae Kim from the Catholic University of Korea Medical School presented a poster on the comparative clinical trial results of DA-2811 and Forxiga. Dong-A ST

According to the company, the clinical results demonstrated that DA-2811 was non-inferior to Forxiga in terms of changes in HbA1c (glycated hemoglobin) after 24 weeks of administration. The company added that DA-2811 showed similar results to Forxiga in metabolic and hepatic indicators such as increased HDL-cholesterol, decreased triglycerides, decreased liver enzyme levels, and decreased uric acid levels. Systolic and diastolic blood pressure, body weight, and waist circumference also decreased to a similar extent as Forxiga.

A Dong-A ST official stated, "This clinical trial is significant in that DA-2811 demonstrated a clinical profile similar to Forxiga not only in blood glucose control but also across metabolic, hepatic, renal, blood pressure, and weight-related indicators. We will continue to build clinical evidence to provide better treatment options for patients in the future."

This content was produced with the assistance of AI translation services.